StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
NBTXBullishCorporate Developmentsnews
High materiality9/10

Nanobiotix advances JNJ-1900; cash runway extended to 2029 on €86m raise

Sep 24, 2026, 4:28 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive clinical signals combined with a sizable equity raise improving liquidity typically support upside if trials show durable efficacy; risk remains tied to later-phase data and execution milestones.

AI summary

What happened, with direct paths to the underlying reporting

Nanobiotix reports encouraging Phase 1 NSCLC results for JNJ-1900 (NBTXR3) and a strong fundraising outcome. Key 12‑month metrics show locoregional control at 79%, LPFS 61%, and OS 70% in 24 patients, with no dose-limiting toxicities. A May 2026 €86m follow-on offering extends cash into 2029, underpinning ongoing CONVERGE and NANORAY-312 program progress.

  • Phase 1 NSCLC data show encouraging efficacy and safety.
  • Oversubscribed €86m follow-on offering extends cash runway to 2029.
  • JNJ-1900 CONVERGE data: ORR 85.7% in unresectable Stage III NSCLC.
  • H1 2026 cash €110.9m; operations funded into 2029.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event